Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
190,5 USD | -0,85 % | -6,46 % | -26,37 % |
17/04 | BIOGEN INC. : UBS se mantiene neutral. | ZM |
17/04 | BIOGEN INC. : Wedbush se mantiene neutral, sin recomendación. | ZM |
Resumen de negocios
- ventas de medicamentos (73,7%): para el tratamiento de la esclerosis múltiple, la psoriasis crónica en adultos, la artritis reumatoide, los cánceres, etc;
- royalties (17,2%) ;
- otros (9,1%): principalmente ingresos procedentes de acuerdos de asociación.
Número de empleados: 7 570
Ventas por actividad
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Innovative Therapies
100,0
%
| 10 173 | 100,0 % | 9 836 | 100,0 % | -3,32 % |
Ventas por región
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
55,2
%
| 5 532 | 54,4 % | 5 434 | 55,2 % | -1,77 % |
Europe
21,8
%
| 2 413 | 23,7 % | 2 140 | 21,8 % | -11,34 % |
Germany
8,8
%
| 926 | 9,1 % | 868 | 8,8 % | -6,28 % |
Asia
8,8
%
| 720 | 7,1 % | 863 | 8,8 % | +19,97 % |
Other
5,4
%
| 583 | 5,7 % | 531 | 5,4 % | -8,87 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Chief Executive Officer | 64 | 14/11/22 | |
Director of Finance/CFO | 60 | 15/08/20 | |
Nicole Murphy
COO | Chief Operating Officer | - | 01/01/15 |
Jane Grogan
CTO | Chief Tech/Sci/R&D Officer | 57 | 02/10/23 |
Chuck Triano
IRC | Investor Relations Contact | - | 10/04/23 |
Michael Hencke
IRO | Public Communications Contact | - | 01/07/12 |
Michael Dambach
TRE | Treasurer | 57 | 01/01/07 |
Corporate Secretary | - | - | |
Robert Kilo
PRN | Corporate Officer/Principal | - | - |
Rachid Izzar
PRN | Corporate Officer/Principal | - | 01/01/21 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 01/01/10 |
William Hawkins
BRD | Director/Board Member | 70 | 19/06/19 |
Caroline Dorsa
CHM | Chairman | 64 | 03/01/10 |
Eric Rowinsky
BRD | Director/Board Member | 67 | 20/03/10 |
Chief Executive Officer | 64 | 14/11/22 | |
Maria Freire
BRD | Director/Board Member | 69 | 02/06/21 |
Director/Board Member | 54 | 01/01 | |
Jesus B. Mantas
BRD | Director/Board Member | 55 | 19/06/19 |
Susan Langer
BRD | Director/Board Member | - | 26/06/23 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 169 160 798 | 144 360 393 ( 85,34 %) | 23 800 000 ( 14,07 %) | 85,34 % |
Participaciones
Nombre | Acciones | % | Valoración |
---|---|---|---|
DENALI THERAPEUTICS INC. 9.16% | 12 751 365 | 9.16% | 261 658 010 $ |
SAGE THERAPEUTICS, INC. 10.38% | 6 241 473 | 10.38% | 116 965 204 $ |
14 652 466 | 7.19% | 9 817 152 $ |
Información de la empresa
Empresas del grupo
Nombre | Categoría y sector |
---|---|
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. |
Biotechnology
|
Biogen International GmbH
Biogen International GmbH Pharmaceuticals: MajorHealth Technology Biogen International GmbH produces pharmaceuticals. It develops medicines for psoriasis and multiple sclerosis. Its products include FUMADERM and BG-12. The company was founded in 1983 and is headquartered in Lucerne, Switzerland. |
Pharmaceuticals: Major
|
Ventas por región
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
-26,37 % | 27,69 mil M | |
-6,08 % | 84,46 mil M | |
+3,95 % | 40,85 mil M | |
+52,09 % | 24,28 mil M | |
-6,59 % | 17,09 mil M | |
-32,37 % | 13,67 mil M | |
-10,45 % | 11,79 mil M | |
-15,88 % | 11,86 mil M | |
-2,85 % | 8067,54 M | |
+0,53 % | 7511,55 M |
- Bolsa de valores
- Acciones
- Acción BIIB
- Empresa Biogen Inc.